Brokers Offer Predictions for NAMS Q4 Earnings

NewAmsterdam Pharma (NASDAQ:NAMS) – Stock analysts at Leerink Partnrs issued their Q4 2025 earnings estimates for shares of NewAmsterdam Pharma in a report issued on Tuesday, December 17th. Leerink Partnrs analyst R. Ruiz anticipates that the company will post earnings per share of ($0.35) for the quarter. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.79) per share. Leerink Partnrs also issued estimates for NewAmsterdam Pharma’s FY2028 earnings at $0.42 EPS.

A number of other equities analysts have also commented on NAMS. Royal Bank of Canada reissued an “outperform” rating and issued a $31.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Scotiabank increased their price objective on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a report on Wednesday, December 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $36.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday, December 5th. Finally, Piper Sandler reissued an “overweight” rating and issued a $37.00 price target on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $36.20.

NewAmsterdam Pharma Price Performance

NewAmsterdam Pharma stock traded down $0.29 during trading hours on Thursday, hitting $25.60. 233,950 shares of the stock were exchanged, compared to its average volume of 373,830. NewAmsterdam Pharma has a 12 month low of $10.29 and a 12 month high of $27.29. The business’s 50-day moving average is $21.01 and its two-hundred day moving average is $18.86.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several institutional investors have recently added to or reduced their stakes in the stock. Banque Cantonale Vaudoise bought a new position in shares of NewAmsterdam Pharma during the second quarter worth about $38,000. Quarry LP raised its holdings in shares of NewAmsterdam Pharma by 2,469.2% in the third quarter. Quarry LP now owns 6,500 shares of the company’s stock valued at $108,000 after purchasing an additional 6,247 shares during the last quarter. Barclays PLC lifted its position in shares of NewAmsterdam Pharma by 1,813.4% in the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock worth $126,000 after purchasing an additional 7,199 shares in the last quarter. Bellevue Group AG acquired a new position in NewAmsterdam Pharma during the third quarter worth $128,000. Finally, XTX Topco Ltd bought a new position in NewAmsterdam Pharma in the third quarter valued at $187,000. 89.89% of the stock is owned by institutional investors.

Insider Buying and Selling at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, major shareholder Nap B.V. Forgrowth sold 8,530 shares of NewAmsterdam Pharma stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $25.02, for a total transaction of $213,420.60. Following the transaction, the insider now directly owns 11,812,033 shares in the company, valued at approximately $295,537,065.66. The trade was a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Louise Frederika Kooij sold 45,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $15.72, for a total value of $707,400.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 252,814 shares of company stock worth $5,970,327. Insiders own 19.50% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.